BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fiorotto R, Amenduni M, Mariotti V, Cadamuro M, Fabris L, Spirli C, Strazzabosco M. Animal models for cystic fibrosis liver disease (CFLD). Biochim Biophys Acta Mol Basis Dis 2019;1865:965-9. [PMID: 30071276 DOI: 10.1016/j.bbadis.2018.07.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Françoise A, Héry-Arnaud G. The Microbiome in Cystic Fibrosis Pulmonary Disease. Genes (Basel) 2020;11:E536. [PMID: 32403302 DOI: 10.3390/genes11050536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
2 Su G, Li Z, Wang R, Lu Y, Nan J, Wu Y, Zhao Y. Signaling pathways involved in p38-ERK and inflammatory factors mediated the anti-fibrosis effect of AD-2 on thioacetamide-induced liver injury in mice. Food Funct 2019;10:3992-4000. [DOI: 10.1039/c8fo02405g] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
3 Zarei K, Meyerholz DK, Stoltz DA. Early intrahepatic duct defects in a cystic fibrosis porcine model. Physiol Rep 2021;9:e14978. [PMID: 34288572 DOI: 10.14814/phy2.14978] [Reference Citation Analysis]
4 Cannito S, Milani C, Cappon A, Parola M, Strazzabosco M, Cadamuro M. Fibroinflammatory Liver Injuries as Preneoplastic Condition in Cholangiopathies. Int J Mol Sci. 2018;19. [PMID: 30518128 DOI: 10.3390/ijms19123875] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
5 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]